<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>TB R&#38;D Matters Blog &#187; TB Prevention and Control Strategies</title>
	<atom:link href="http://blog.newtbdrugs.org/category/tb-prevention-and-control/feed/" rel="self" type="application/rss+xml" />
	<link>http://blog.newtbdrugs.org</link>
	<description>Working Towards a Faster Cure for Tuberculosis</description>
	<lastBuildDate>Wed, 08 Sep 2010 18:14:02 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.9.1</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Interview with Dr. Lee Reichman &#8211; Part Three</title>
		<link>http://blog.newtbdrugs.org/2010/09/interview-with-dr-lee-reichman-part-three/</link>
		<comments>http://blog.newtbdrugs.org/2010/09/interview-with-dr-lee-reichman-part-three/#comments</comments>
		<pubDate>Fri, 03 Sep 2010 14:15:32 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[TB Prevention and Control Strategies]]></category>
		<category><![CDATA[Video]]></category>
		<category><![CDATA[Voices from the Fight to Stop Tuberculosis]]></category>
		<category><![CDATA[usa]]></category>
		<category><![CDATA[voices]]></category>

		<guid isPermaLink="false">http://blog.newtbdrugs.org/?p=1538</guid>
		<description><![CDATA[<a href=http://blog.newtbdrugs.org/2010/09/interview-with-dr-lee-reichman-part-three/><img src="http://blog.newtbdrugs.org/wp-content/uploads/2010/07/lee-reichman-150x150.png" class="imgtfe" hspace="5" width="100"  border=0></a>This is part three of our interview with Lee B. Reichman, MD, MPH, Founding Executive Director of the New Jersey Medical School Global Tuberculosis Institute, and Professor of Medicine, Preventive Medicine and Community Health at the New Jersey Medical School, in Newark, New Jersey.]]></description>
		<wfw:commentRss>http://blog.newtbdrugs.org/2010/09/interview-with-dr-lee-reichman-part-three/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Interview with Dr. Lee Reichman – Part Two</title>
		<link>http://blog.newtbdrugs.org/2010/08/interview-with-dr-lee-reichman-%e2%80%93-part-two/</link>
		<comments>http://blog.newtbdrugs.org/2010/08/interview-with-dr-lee-reichman-%e2%80%93-part-two/#comments</comments>
		<pubDate>Thu, 26 Aug 2010 17:01:50 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[TB Prevention and Control Strategies]]></category>
		<category><![CDATA[Video]]></category>
		<category><![CDATA[Voices from the Fight to Stop Tuberculosis]]></category>
		<category><![CDATA[usa]]></category>
		<category><![CDATA[voices]]></category>

		<guid isPermaLink="false">http://blog.newtbdrugs.org/?p=1531</guid>
		<description><![CDATA[<a href=http://blog.newtbdrugs.org/2010/08/interview-with-dr-lee-reichman-%e2%80%93-part-two/><img src="http://blog.newtbdrugs.org/wp-content/uploads/2010/07/lee-reichman-150x150.png" class="imgtfe" hspace="5" width="100"  border=0></a>This is part two of our interview with Lee B. Reichman, MD, MPH, Founding Executive Director of the  New Jersey Medical School Global Tuberculosis Institute, and Professor  of Medicine, Preventive Medicine and Community Health at the New Jersey  Medical School, in Newark, New Jersey.]]></description>
		<wfw:commentRss>http://blog.newtbdrugs.org/2010/08/interview-with-dr-lee-reichman-%e2%80%93-part-two/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>Open Forum 4: Why TB Matters to Women&#8217;s Health</title>
		<link>http://blog.newtbdrugs.org/2010/08/open-forum-4-why-tb-matters-to-womens-health/</link>
		<comments>http://blog.newtbdrugs.org/2010/08/open-forum-4-why-tb-matters-to-womens-health/#comments</comments>
		<pubDate>Tue, 17 Aug 2010 13:53:25 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[TB Prevention and Control Strategies]]></category>
		<category><![CDATA[women's health]]></category>

		<guid isPermaLink="false">http://blog.newtbdrugs.org/?p=1474</guid>
		<description><![CDATA[<a href=http://blog.newtbdrugs.org/2010/08/open-forum-4-why-tb-matters-to-womens-health/><img src="http://blog.newtbdrugs.org/wp-content/uploads/2010/08/Mother-And-Child-900x833-250x231.jpg" class="imgtfe" hspace="5" width="100"  border=0></a>From Citizen News Service: TUBERCULOSIS (TB) has a major impact on women's sexual reproductive health and that of their children. For pregnant women living in areas with high TB infection rates, there are increased chances of transmission of TB to a child before, during delivery or after birth. The disease, especially if associated with HIV, also accounts for a high incidence of maternal and infant mortality. Unfortunately, there is little to no attention to women's vulnerability in the current discussion and media blitz of a resurgent TB internationally, and in particular, sub-Saharan Africa.]]></description>
		<wfw:commentRss>http://blog.newtbdrugs.org/2010/08/open-forum-4-why-tb-matters-to-womens-health/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Interview with Dr. Lee Reichman &#8211; Part One</title>
		<link>http://blog.newtbdrugs.org/2010/07/interview-with-dr-lee-reichman/</link>
		<comments>http://blog.newtbdrugs.org/2010/07/interview-with-dr-lee-reichman/#comments</comments>
		<pubDate>Fri, 30 Jul 2010 19:16:25 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[TB Prevention and Control Strategies]]></category>
		<category><![CDATA[Video]]></category>
		<category><![CDATA[Voices from the Fight to Stop Tuberculosis]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[voices]]></category>

		<guid isPermaLink="false">http://blog.newtbdrugs.org/?p=1340</guid>
		<description><![CDATA[<a href=http://blog.newtbdrugs.org/2010/07/interview-with-dr-lee-reichman/><img src="http://blog.newtbdrugs.org/wp-content/uploads/2010/07/lee-reichman-150x150.png" class="imgtfe" hspace="5" width="100"  border=0></a>This is part one of our interview with Lee B. Reichman, MD, MPH, Founding Executive Director of the  New Jersey Medical School Global Tuberculosis Institute, and Professor  of Medicine, Preventive Medicine and Community Health at the New Jersey  Medical School, in Newark, New Jersey.]]></description>
		<wfw:commentRss>http://blog.newtbdrugs.org/2010/07/interview-with-dr-lee-reichman/feed/</wfw:commentRss>
		<slash:comments>2</slash:comments>
		</item>
		<item>
		<title>Vienna 2010: Citizen News Service Correspondent Statement on IPT</title>
		<link>http://blog.newtbdrugs.org/2010/07/vienna-2010-citizen-news-service-correspondent-statement-on-ipt/</link>
		<comments>http://blog.newtbdrugs.org/2010/07/vienna-2010-citizen-news-service-correspondent-statement-on-ipt/#comments</comments>
		<pubDate>Fri, 23 Jul 2010 15:11:47 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[TB Prevention and Control Strategies]]></category>
		<category><![CDATA[TB Treatment]]></category>
		<category><![CDATA[tb/hiv]]></category>
		<category><![CDATA[treatment]]></category>

		<guid isPermaLink="false">http://blog.newtbdrugs.org/?p=1321</guid>
		<description><![CDATA[<a href=http://blog.newtbdrugs.org/2010/07/vienna-2010-citizen-news-service-correspondent-statement-on-ipt/><img src="http://blog.newtbdrugs.org/wp-content/uploads/2010/07/CNS-logo.png" class="imgtfe" hspace="5" width="100"  border=0></a>Citizen News Service correspondent, Bobby Ramakant, reiterates the call from the Stop TB Working Group on TB/HIV to introduce Isoniazid prevention therapy to prevent the progression of latent TB infection to active disease. Effective IPT treatment reduces the development of active TB disease in 40-60% of patients. The content of this post originally appeared in an email sent to the Stop TB Health Dev mailing list.]]></description>
		<wfw:commentRss>http://blog.newtbdrugs.org/2010/07/vienna-2010-citizen-news-service-correspondent-statement-on-ipt/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>WHO Releases Factsheet on Children and TB</title>
		<link>http://blog.newtbdrugs.org/2010/07/who-releases-factsheet-on-children-and-tb/</link>
		<comments>http://blog.newtbdrugs.org/2010/07/who-releases-factsheet-on-children-and-tb/#comments</comments>
		<pubDate>Fri, 02 Jul 2010 19:29:20 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[TB Prevention and Control Strategies]]></category>
		<category><![CDATA[children]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://blog.newtbdrugs.org/?p=1196</guid>
		<description><![CDATA[<a href=http://blog.newtbdrugs.org/2010/07/who-releases-factsheet-on-children-and-tb/><img src=http://blog.newtbdrugs.org/wp-content/uploads/2010/03/Picture-6-150x150.png class=imgtfe hspace=5 align=left width=100  border=0></a>Over 250,000 children develop TB and 100,000 children will continue to die each year from TB. A child usually gets TB infection from being exposed to a sputum-positive adult. Young children below ten years of age are at risk of becoming infected with TB bacilli. They are also at high risk of developing active tuberculosis because the immune system of young children is less developed.]]></description>
		<wfw:commentRss>http://blog.newtbdrugs.org/2010/07/who-releases-factsheet-on-children-and-tb/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The War on Tuberculosis &#8211; DOTS in Newark, NJ</title>
		<link>http://blog.newtbdrugs.org/2010/06/the-war-on-tuberculosis-dots-in-newark/</link>
		<comments>http://blog.newtbdrugs.org/2010/06/the-war-on-tuberculosis-dots-in-newark/#comments</comments>
		<pubDate>Wed, 30 Jun 2010 13:00:02 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[TB Prevention and Control Strategies]]></category>
		<category><![CDATA[community]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[usa]]></category>

		<guid isPermaLink="false">http://blog.newtbdrugs.org/?p=1141</guid>
		<description><![CDATA[<a href=http://blog.newtbdrugs.org/2010/06/the-war-on-tuberculosis-dots-in-newark/><img src="http://blog.newtbdrugs.org/wp-content/uploads/2010/06/leifer-amd-meskel-250x192.png" class="imgtfe" hspace="5" width="100"  border=0></a>Haile Meskel emerges from his Newark, New Jersey, row house and slips into the passenger seat of a shiny, late-model sedan, where a woman waits for him, a tiny white envelope and bottled water at the ready. He swallows a handful of pills as the woman watches. Within a couple of minutes the transaction is over. To the casual observer, this might look like one of the many furtive, illegal transactions that take place in this city every day—but it's no drug deal. This is an example of directly observed therapy (DOT), which many public health and infectious disease experts believe is the single best method of treating people infected with tuberculosis and controlling the spread of multidrug-resistant and extensively drug-resistant strains in the United States and around the world.]]></description>
		<wfw:commentRss>http://blog.newtbdrugs.org/2010/06/the-war-on-tuberculosis-dots-in-newark/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Future of Olive View TB Ward in Doubt</title>
		<link>http://blog.newtbdrugs.org/2010/06/future-of-olive-view-tb-ward-in-doubt/</link>
		<comments>http://blog.newtbdrugs.org/2010/06/future-of-olive-view-tb-ward-in-doubt/#comments</comments>
		<pubDate>Mon, 28 Jun 2010 16:20:08 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[TB News]]></category>
		<category><![CDATA[TB Prevention and Control Strategies]]></category>
		<category><![CDATA[community]]></category>
		<category><![CDATA[funding]]></category>
		<category><![CDATA[usa]]></category>

		<guid isPermaLink="false">http://blog.newtbdrugs.org/?p=1132</guid>
		<description><![CDATA[<a href=http://blog.newtbdrugs.org/2010/06/future-of-olive-view-tb-ward-in-doubt/><img src="http://blog.newtbdrugs.org/wp-content/uploads/2010/06/DrChin-Patient-5501-500x381.jpg" class="imgtfe" hspace="5" width="100"  border=0></a>Los Angeles County is spending more than $16 million to build a  dedicated tuberculosis ward that also could serve as a treatment center  to isolate victims of a bioterrorism attack. But something’s missing: people to staff it.]]></description>
		<wfw:commentRss>http://blog.newtbdrugs.org/2010/06/future-of-olive-view-tb-ward-in-doubt/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Sanatorium Files Part One: Timeline</title>
		<link>http://blog.newtbdrugs.org/2010/06/the-sanatorium-files-part-one-timeline/</link>
		<comments>http://blog.newtbdrugs.org/2010/06/the-sanatorium-files-part-one-timeline/#comments</comments>
		<pubDate>Fri, 18 Jun 2010 15:35:36 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[TB Prevention and Control Strategies]]></category>
		<category><![CDATA[history]]></category>

		<guid isPermaLink="false">http://blog.newtbdrugs.org/?p=1073</guid>
		<description><![CDATA[<a href=http://blog.newtbdrugs.org/2010/06/the-sanatorium-files-part-one-timeline/><img src="http://blog.newtbdrugs.org/wp-content/uploads/2010/06/Bethesda-Sanatorium-1920.jpg" class="imgtfe" hspace="5" width="100"  border=0></a>This post launches a new series on NewTBDrugs.org called “The Sanatorium Files,” which will explore how medical practitioners, caregivers, society and governments have fought the ongoing TB epidemic and the impact these treatments had and have on the patients receiving them. This first post in the series is a timeline showing the evolution of tuberculosis treatments, ranging from the harmless but useless to the painful, bizarre and dangerous, and ultimately leading to the antibiotics used to treat the disease for the last 30-40 years.]]></description>
		<wfw:commentRss>http://blog.newtbdrugs.org/2010/06/the-sanatorium-files-part-one-timeline/feed/</wfw:commentRss>
		<slash:comments>5</slash:comments>
		</item>
		<item>
		<title>TB REACH announces US$ 18.4 million in grants for innovation in tuberculosis case finding</title>
		<link>http://blog.newtbdrugs.org/2010/05/tb-reach-announces-us-18-4-million-in-grants-for-innovation-in-tuberculosis-case-finding/</link>
		<comments>http://blog.newtbdrugs.org/2010/05/tb-reach-announces-us-18-4-million-in-grants-for-innovation-in-tuberculosis-case-finding/#comments</comments>
		<pubDate>Wed, 05 May 2010 14:46:35 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[TB News]]></category>
		<category><![CDATA[TB Prevention and Control Strategies]]></category>
		<category><![CDATA[case detection]]></category>
		<category><![CDATA[stop tb]]></category>
		<category><![CDATA[TB REACH]]></category>

		<guid isPermaLink="false">http://blog.newtbdrugs.org/?p=873</guid>
		<description><![CDATA[<a href=http://blog.newtbdrugs.org/2010/05/tb-reach-announces-us-18-4-million-in-grants-for-innovation-in-tuberculosis-case-finding/><img src="http://blog.newtbdrugs.org/wp-content/uploads/2010/04/STOPTB_COLOR_MAP_web-250x82.jpg" class="imgtfe" hspace="5" width="100"  border=0></a>The Stop TB Partnership's TB REACH initiative today announced the recipients of its first wave of grants to organizations that will engage in innovative approaches to increasing detection of tuberculosis (TB).]]></description>
		<wfw:commentRss>http://blog.newtbdrugs.org/2010/05/tb-reach-announces-us-18-4-million-in-grants-for-innovation-in-tuberculosis-case-finding/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
